CN105456276A - Medicine for alleviating body injury resulting from infection of influenza virus - Google Patents
Medicine for alleviating body injury resulting from infection of influenza virus Download PDFInfo
- Publication number
- CN105456276A CN105456276A CN201510958363.0A CN201510958363A CN105456276A CN 105456276 A CN105456276 A CN 105456276A CN 201510958363 A CN201510958363 A CN 201510958363A CN 105456276 A CN105456276 A CN 105456276A
- Authority
- CN
- China
- Prior art keywords
- medicine
- infection
- dihydrotestosterone
- influenza
- influenza virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Abstract
The invention provides a medicine for alleviating body injury resulting from infection of influenza virus. An active ingredient of the medicine is androgen. Preferably, an active ingredient of the medicine is dihydrotestosterone. According to the medicine, the protection effect of the androgen on male mice after the infection of influenza virus is disclosed for the first time, the discovery of the mechanism is of high clinical significance, and a solid foundation can be laid for optimization of male influenza prevention measures and therapeutic methods.
Description
Technical field
The present invention relates to immunology and epidemiology field, specifically, relate to and a kind ofly alleviate the medicine that influenza infection causes body injury.
Background technology
Influenza is one of modal infectious disease of the mankind, and influenza virus, along with in birds, circulation between domestic animal and the mankind and constantly making a variation, occurs that the threat of the new recombinant virus across species barrier exists forever.
In order to the mechanism of causing a disease studied flu virus further, usually need to build influenza infection BALB/c animal model, directly isolated influenza virus from infection human body, initial not infecting mouse effectively, need constantly at mice interior generation, the virulence of strain and pathogenicity are changed, makes Mus lung adapted strain, thus set up the mouse nuclei of influenza virus.Continuous passage in the body that some virulent strain does not need to carry out animal subject, can direct infection animal subject, sets up infection model.As Sun Huihui, (A/California/7/2009 and A/California/4/2009 virus infectivity compares, Bao Linlin etc.; China's comparative medicine magazine, 2010.01) animal model of the BALB/c mouse H1N1 influenza virus (A/California/7/2009) of setting up, namely establishes infection model without the continuous passage in BALB/c mouse body.
At present, the clinical research about influenza and influenza virus carries out data analysis not in accordance with sex usually, or laboratory animal does not report sex.To the invention provides after influenza infection animal the cause of disease difference that a situation arises between both sexes, and this species diversity is because the effect difference of gonadal hormone for inflammatory and immune response causes.The present invention intends by mice viral infection test, the relation of research androgen and influenza virus and host immune system, try hard to there is new breakthrough, for the new medicament screen and clinical treatment preventing and treating influenza provides theoretical foundation and target on the molecular mechanism research caused a disease of androgen and influenza virus and host.
Summary of the invention
The object of this invention is to provide and a kind ofly alleviate the medicine that influenza infection causes body injury.
In order to realize the object of the invention, of the present inventionly a kind ofly alleviate the medicine that influenza infection causes body injury, its effective ingredient is androgen.
Preferably, of the present inventionly a kind ofly alleviate the medicine that influenza infection causes body injury, its effective ingredient is dihydrotestosterone (DHT).
Also containing vitamin C (VC) in described medicine, the mass ratio of DHT and VC is 1:2-10, preferred 1:4.
Medicine of the present invention is the dosage forms such as solution, Emulsion, suspensoid, injection.
More preferably, described medicine is that dihydrotestosterone and vitamin C are dissolved in the injection made in Fructus Maydis oil.The single dose unit of described injection is: dihydrotestosterone 0.5-1.5mg/kg body weight; Catergen-10mg/kg body weight, preferred 4mg/kg body weight.Adopt hypodermic mode administration.
The present invention also provides the preparation method of above-mentioned injection: take DHT, VC in proportion, adds in Fructus Maydis oil, stirs 1 hours, treats that DHT and VC dissolves completely, to obtain final product.
The present invention also provides androgen causing application in the medicine of body injury for the preparation of alleviating influenza infection.
The present invention also provides dihydrotestosterone causing application in the medicine of body injury for the preparation of alleviating influenza infection.
The present invention passes through influenza infection male mice, and use androgen process mice, find processed group than matched group sickness rate and mortality rate low, carry out the analysis of inflammatory cell sum and various inflammatory cell ratio in pathology detection and alveolar infusion liquid (BALF) subsequently, and pass through the experimental result of cellular level experimental verification histopathology.
After the present invention discloses influenza infection first, androgen is to the protective effect of male mice, and the discovery of this mechanism has stronger clinical meaning, can provide solid foundation for the preventive measure of male influenza and Therapeutic Method optimization.
Accompanying drawing explanation
Fig. 1 is the situation of change of body weight, body temperature, survival rate after each experimental mice infection WSN virus in the embodiment of the present invention 1.
Fig. 2 is the variation diagram of total cell quantity and neutrophilic granulocyte, macrophage and percentage of lymphocyte in the mice alveolar infusion liquid of each experimental group in the embodiment of the present invention 1.
Fig. 3 infects WSN virus within 9 days, to dissect the section of mice gained lung tissue afterwards in the embodiment of the present invention 1.
Fig. 4 infects WSN virus expression of the relevant Marker of M1 with M2 in pulmonary alveolar macrophage after 9 days in the embodiment of the present invention 1.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.If do not specialize, the conventional means that technological means used in embodiment is well known to those skilled in the art, is raw materials usedly commercial goods.
The vitamin C used in the present invention, chemical name L-AA, writes a Chinese character in simplified form VC, CASNo.50-81-7, molecular formula C
6h
8o
6, molecular weight 176.12.
Embodiment 1 androgen is causing application in the medicine of body injury for the preparation of alleviating influenza infection
Cause the injection of body injury for alleviating influenza infection, injection formula is as follows: DHT0.0125g, VC0.05g, Fructus Maydis oil 50mL.
Take DHT, VC in proportion, add in Fructus Maydis oil, stir 1 hours, treat that DHT and VC dissolves completely, to obtain final product.
1. mouse infection influenza virus: male C57BL/6 Mus 2-3 monthly age, body weight being about 25g is divided into experimental group 1, experimental group 2, experimental group 3 at random, often organizes 10.After ether light anesthesia, three experimental mice collunariums inoculation influenza virus WSN virus liquid 50 μ l (3000pfu).After three experimental mice virus inoculations, experimental group 1 mouse subcutaneous injection Fructus Maydis oil (oil) 0.1mL, experimental group 2 mouse subcutaneous injection is containing the Fructus Maydis oil 0.1mL of 1mgDHT, and experimental group 3 mouse subcutaneous injection is containing the Fructus Maydis oil 0.1mL of 1mgDHT and 4mgVC.Then record mouse temperature body weights every day, to catch an illness rate and fatality rate to detect mice.
After each experimental mice infection WSN virus, the situation of change of body weight, body temperature, survival rate as shown in Figure 1.As can be seen from Figure 1, DHT group and DHT+VC group can suppress the infection of virus, can improve the survival rate of mice.
Result shows, DHT+VC group is than single medicine DHT group better effects if, wherein in DHT+VC group, the most remarkable by DHT1mg/kg body weight/d, VC4mg/kg body weight/d administering effect.
Fig. 2 is the variation diagram of total cell number, neutrophilic granulocyte, macrophage and percentage of lymphocyte in each experimental mice alveolar infusion liquid.
3. infect WSN virus and dissect mice after 9 days, carry out the degree that pathological section analyzes pneumonia reaction.
Fig. 3 is shown in the section of each experimental mice lung tissue.
4. be separated and infect the mouse alveolar macrophages of WSN virus after 9 days, detect the Marker. of the Marker of the proinflammatory relevant M1 macrophage M2 macrophage relevant with inflammation-inhibiting as shown in Figure 4, cellular level experiment shows, DHT process and DHT+VC process can suppress the Marker of M1 macrophage in pulmonary alveolar macrophage to express, and promote the expression of the Marker of M2 macrophage.
The experimental result of tissue and cellular level all shows, injection prepared by the present invention by suppressing the inflammatory reaction of pulmonary, thus can reduce the infection of male mice virus effectively, can suppress the sickness rate after mouse infection, improve the survival rate of mice.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (8)
1. alleviate the medicine that influenza infection causes body injury, it is characterized in that, its effective ingredient is androgen.
2. medicine according to claim 1, is characterized in that, its effective ingredient is dihydrotestosterone.
3. medicine according to claim 2, is characterized in that, also containing vitamin C in described medicine, dihydrotestosterone and ascorbic mass ratio are 1:2-10, preferred 1:4.
4. the medicine according to any one of claim 1-3, is characterized in that, described medicine is solution, Emulsion, suspensoid, injection.
5. medicine according to claim 4, is characterized in that, it is that dihydrotestosterone and vitamin C are dissolved in the injection made in Fructus Maydis oil.
6. medicine according to claim 5, is characterized in that, single dose unit is: dihydrotestosterone 0.5-1.5mg/kg body weight; Catergen-10mg/kg body weight, preferred 4mg/kg body weight.
7. androgen is causing application in the medicine of body injury for the preparation of alleviating influenza infection.
8. dihydrotestosterone is causing application in the medicine of body injury for the preparation of alleviating influenza infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510958363.0A CN105456276A (en) | 2015-12-18 | 2015-12-18 | Medicine for alleviating body injury resulting from infection of influenza virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510958363.0A CN105456276A (en) | 2015-12-18 | 2015-12-18 | Medicine for alleviating body injury resulting from infection of influenza virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456276A true CN105456276A (en) | 2016-04-06 |
Family
ID=55594742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510958363.0A Pending CN105456276A (en) | 2015-12-18 | 2015-12-18 | Medicine for alleviating body injury resulting from infection of influenza virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456276A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007045027A1 (en) * | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| CN101332174A (en) * | 2008-06-20 | 2008-12-31 | 上海汇伦生命科技有限公司 | Dihydrotestosterone external preparation and pharmaceutical use thereof |
-
2015
- 2015-12-18 CN CN201510958363.0A patent/CN105456276A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007045027A1 (en) * | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| CN101332174A (en) * | 2008-06-20 | 2008-12-31 | 上海汇伦生命科技有限公司 | Dihydrotestosterone external preparation and pharmaceutical use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 何芳等: "微营养素对致衰小鼠雄激素水平的影响及抗氧化作用研究", 《达能营养中心第十届学术年会论文集》 * |
| 黄超宾: "TGF-β1在流感病毒引起的睾丸免疫反应中的调节作用", 《中国博士学位论文全文数据库农业科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marchini et al. | Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade | |
| Hurdayal et al. | The role of IL-4 and IL-13 in cutaneous Leishmaniasis | |
| Sun et al. | Matrine exhibits antiviral activity in a PRRSV/PCV2 co-infected mouse model | |
| Pia | SARS-CoV-2-reactive T cells in patients and healthy donors | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| CN113082049B (en) | New application of potassium iodide or composition containing potassium iodide in preparation of drugs for treating African swine fever | |
| CN111588721A (en) | New application of compound ZL0580 in preventing or treating African swine fever | |
| Prabhu et al. | Cyanobacterial metabolites as novel drug candidates in corona viral therapies: A review | |
| Dhama et al. | SARS-CoV-2 emerging omicron subvariants with a special focus on BF. 7 and XBB. 1.5 recently posing fears of rising cases amid ongoing COVID-19 pandemic. | |
| Alam | Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities | |
| CN104398526A (en) | Application of triptolide and tripterine in preparation of antitumor drugs | |
| Ou et al. | Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus | |
| CN105456276A (en) | Medicine for alleviating body injury resulting from infection of influenza virus | |
| CN104083433A (en) | External veterinary medicine composition for treating animal scabies, and application and preparation method thereof | |
| CN101946771B (en) | Application of Saikosaponin A to preparing pesticide for resisting tobacco mosaic virus (TMV) | |
| CN105769832A (en) | Medicine for reducing body injuries caused by influenza virus infection | |
| CN111686107B (en) | New application of compound PLX51107 in preparation of drug for preventing or treating African swine fever | |
| CN101946784B (en) | Application of ginkgolides B to preparation of tobacco mosaic virus resistant medicament | |
| CN104042621A (en) | Use of andrographolide and its derivatives in preparation of drugs for preventing and treating hand-foot-and-mouth disease | |
| CN111658654A (en) | New application of compound JQ-1 in preventing or treating African swine fever | |
| CN105193784A (en) | Application of ginkgetin in preparation of drugs for treating streptococcus suis infection | |
| Zhao et al. | Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F (ab′) 2 | |
| CN103169970A (en) | Pharmaceutical composition for treating viral pneumonia | |
| CN102697832B (en) | Applications of honeysuckle flower water extract and let-7a microRNA (Ribonucleic Acid) in preparation of medicament and health-care product for preventing and treating dengue viruses and dengue fever | |
| Wu et al. | Cutaneous adverse reactions associated with COVID-19 vaccines: Current evidence and potential immune mechanisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |
|
| RJ01 | Rejection of invention patent application after publication |